Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?

(2020) Alexander Höllein et al.   Cancer Genetics

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

(2020) Andrew H. Wei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

(2019) Gerwin Huls et al.   BLOOD

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

(2019) Peter Valent et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern

(2019) Luca Vincenzo Cappelli et al.   LEUKEMIA

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA

(2019) Laxmi Parida et al.   PLoS Computational Biology

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

(2018) Kiyomi Morita et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

(2018) Maja Rothenberg-Thurley et al.   LEUKEMIA

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia

(2018) Chi Young Ok et al.   HAEMATOLOGICA

Prediction of acute myeloid leukaemia risk in healthy individuals

(2018) Sagi Abelson et al.   NATURE

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

(2018) Jorge E. Cortes et al.   LEUKEMIA

Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia

(2017) Jay L. Patel et al.   LEUKEMIA RESEARCH

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal

(2017) Peter Valent et al.   EBioMedicine

Persistence ofDNMT3AR882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

(2016) Bhavana Bhatnagar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in AML: prognostic and therapeutic implications

(2016) C. D. DiNardo et al.   Hematology-American Society of Hematology Education Program

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

(2015) Houria Debarri et al.   Oncotarget

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD